Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-06-29Clinical Trial Update: Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery [Phase 4]
Phase 4 clinical trial evaluating the ocular-hypertensive response to topical steroids in children after bilateral strabismus surgery; study…
-
FDA label_change · 2016-06-16FDA Approved: BETOPTIC S — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for BETOPTIC S (betaxolol hydrochloride) submitted by Novartis, resulting in labeling changes fo…
-
CLINICAL_TRIALS trial_result · 2016-06-06Clinical Trial Update: Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease [Phase 2]
Phase 2 safety and efficacy trial comparing Catioprost (unpreserved latanoprost 0.005% emulsion) with Travatan Z for glaucoma and ocular sur…
-
CLINICAL_TRIALS trial_result · 2016-05-30Clinical Trial Update: Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial update for SPARC0912 and Reference0912 in open angle glaucoma and ocular hypertension; results posted in 2016.
-
CLINICAL_TRIALS research · 2016-05-26Clinical Trial Update: A Phase I Clinical Trial of DARC [Phase 1]
Phase I clinical trial update for DARC in glaucoma-related conditions; the trial status is currently UNKNOWN.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-05-13Clinical Trial Update: Intra-observer and Inter-observer Variability With Dynamic Contour Tonometry.
The clinical trial investigated intra- and inter-observer variability in dynamic contour tonometry for intraocular pressure measurements, bu…
-
CLINICAL_TRIALS research · 2016-05-12Clinical Trial Update: Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml [Phase 4]
A Phase 4 clinical trial update examining the intraocular pressure effects and tolerability of bimatoprost 0.01% and preservative-free taflu…
-
FDA approval · 2016-05-05FDA Approved: ALPHAGAN P — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for ALPHAGAN P (brimonidine tartrate), approving changes to the product labeling requested by Allerg…
-
CLINICAL_TRIALS trial_result · 2016-05-05Clinical Trial Update: Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial evaluating safety of SPARC0913 in open angle glaucoma and ocular hypertension has completed with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-04-27Clinical Trial Update: 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension [Phase 1]
Phase 1 study evaluating safety and activity of 5 escalating doses of SAR366234 plus a single dose of latanoprost in open-angle glaucoma or …
-
FDA approval · 2016-04-22FDA Approved: LATANOPROST — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved a generic latanoprost product from Rising Pharma Holdings, Inc. via an Original Application (ANDA 202442) to reduce intraoc…
-
FDA approval · 2016-04-19FDA Approved: BIMATOPROST — Original Application (Sandoz Inc)
FDA approved the original ANDA for bimatoprost ophthalmic solution by Sandoz, establishing a generic version of this glaucoma medication.
-
FDA label_change · 2016-03-24FDA Approved: BETOPTIC S — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Betoptic S (betaxolol hydrochloride) from Novartis, updating the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2016-03-14Clinical Trial Update: The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure
A completed trial update evaluating the diurnal and nocturnal effects of Simbrinza and Timolol on intraocular pressure and ocular perfusion …
-
FDA label_change · 2016-03-11FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Travatan Z (travoprost) from Novartis Pharmaceuticals Corporation. This action updates the produ…
-
CLINICAL_TRIALS trial_result · 2016-02-25Clinical Trial Update: A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG) [Phase 2]
Phase 2, 28-day study of ONO-9054 ophthalmic solution in ocular hypertension and open-angle glaucoma has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients [NA]
Clinical trial NCT02342288 completed; results for intraoperative ocular pressure in lumbar spine fusion patients were posted in 2016.
-
FDA label_change · 2016-01-20FDA Approved: SIMBRINZA — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for SIMBRINZA (brinzolamide/brimonidine tartrate) submitted by Alcon Laboratories, Inc., resulting i…
-
FDA approval · 2016-01-19FDA Approved: BRIMONIDINE TARTRATE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for brimonidine tartrate submitted by Sandoz Inc, resulting in changes to the product's labeling…
-
FDA label_change · 2016-01-15FDA Approved: SIMBRINZA — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application for SIMBRINZA (brinzolamide/brimonidine tartrate) to update the product labeling.
-
CLINICAL_TRIALS trial_result · 2016-01-14Clinical Trial Update: Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension [Phase 4]
Phase 4 trial comparing bimatoprost 0.01% alone with travoprost 0.004% and timolol 0.5% in glaucoma or ocular hypertension. Results were pos…
-
CLINICAL_TRIALS trial_result · 2015-12-29Clinical Trial Update: 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Phase 2]
A Phase 2 proof-of-concept study evaluated a fixed-dose Travoprost/brinzolamide ophthalmic suspension in open-angle glaucoma or ocular hyper…
-
FDA approval · 2015-12-09FDA Approved: LATANOPROST — Supplemental Application (Bausch & Lomb Incorporated)
The FDA approved a supplemental application for latanoprost filed by Bausch & Lomb Incorporated.
-
CLINICAL_TRIALS trial_result · 2015-12-09Clinical Trial Update: A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Clinical trial update for GANFORT UD in primary open-angle glaucoma or ocular hypertension has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2015-11-30Clinical Trial Update: An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension [Phase 4]
Phase 4 trial comparing efficacy and safety of bimatoprost 0.01% alone with travoprost 0.004% and timolol 0.5% in glaucoma or ocular hyperte…